Clinical Trial Update: Brain Metastases In ErbB2-Positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of lapatinib for ErbB2-positive breast cancer with brain metastases was terminated, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer

Drugs mentioned

• Tykerb (lapatinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Breast | Phase 2 | Status: TERMINATED | Results posted: 2012-10-15